

2022/9/5

9月9日から Paris で開催される ESMO にて JACCRO GC-08 の最終的な OS, PFS などの成績が聖マリアンナ医科大学砂川教授から報告されます



Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08)

Yu Sunakawa¹, Eisuke Inoue², Yasuhiro Sakamoto³, Ryohei Kawabata⁴, Atsushi Ishiguro⁵, Yusuke Akamaru⁶, Yosuke Kito⁷, Masazumi Takahashi⁸, Jin Matsuyama⁹, Hiroshi Yabusaki¹⁰, Akitaka Makiyama¹¹, Takahisa Suzuki¹², Masahiro Tsuda¹³, Hisateru Yasui¹⁴, Hisato Kawakami¹⁵, Takako Eguchi Nakajima¹⁶, Kei Muro¹⁷, Ryo Matoba¹⁸, Wataru Ichikawa¹⁹, and Masashi Fujii²⁰
On behalf of the JACCRO GC-08 investigators

¹Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan; ²Showa University Research Administration Center, Tokyo, Japan; ³Department of Medical Oncology, Osaka Citizen Hospital, Osaka, Japan; ⁴Department of Surgery, Osaka Rosai Hospital, Sakai, Japan; ⁵Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan; ⁶Department of Gastroenterological Surgery, Ikeda City Hospital, Ikeda, Japan; ⁷Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan; ⁸Division of Gastroenterological Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan; ⁹Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan; ¹⁰Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan; ¹¹Cancer Center, Gifu University Hospital, Gifu, Japan; ¹²Department of Surgery, National Hospital Organization Kure Medical Center, Kure, Japan; ¹³Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan; ¹⁴Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan; ¹⁵Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; ¹⁶Department of Early Clinical Development, Kyoto University Graduate School of Medicine; ¹⁷Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan; ¹⁸DNA Chip Research Inc., Tokyo, Japan; ¹⁹Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan; ²⁰Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan;



Japan Clinical Cancer Research Organization (JACCRO)

JACCRO CC-17 : *RAS* 遺伝子変異型腫瘍を有する切除不能進行・再発大腸癌患者における化学療法後の血液中*RAS* 遺伝子変異を評価する観察研究 (RASMEX study) の症例集積が完遂しました。

2021 年から登録が開始され 2022 年 8 月 23 日に目標の 300 例の集積が完了しました。本研究に参加された御施設の方ならびに患者様に感謝申し上げます。

本試験の成果は今後の *RAS* 遺伝子変異型の患者様の二次治療の選択に大きく貢献できると考えています。

早急にデータを解析し、ASCO GI 2023 ならびに ASCO 2023 にて公表致します。

有難うございました。